Open · 605 days left D National Institutes of Health

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Funding
$650,000
Deadline
--
Days
--
Hrs
--
Min
--
Sec
Oct 19, 2027
Posted Dec 11, 2024 (436 days ago)
Closes Oct 19, 2027 (in 605 days)

Grant Details

Opportunity Number
PAR-25-296
CFDA / ALN
93.121, 93.172, 93.307, 93.313, 93.350, 93.846, 93.855, 93.859, 93.865
Opportunity Category
Discretionary (D)
Funding Category
HL, ISS
Funding Instrument
Cooperative Agreement (CA)
Cost Sharing
No Cost Sharing (No)

Eligibility

Public and State controlled institutions of higher education (06)

Other Eligible Applicants include the following: See NOFO for further eligibility criteria. Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Description

The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.